JP2011515490A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515490A5
JP2011515490A5 JP2011502032A JP2011502032A JP2011515490A5 JP 2011515490 A5 JP2011515490 A5 JP 2011515490A5 JP 2011502032 A JP2011502032 A JP 2011502032A JP 2011502032 A JP2011502032 A JP 2011502032A JP 2011515490 A5 JP2011515490 A5 JP 2011515490A5
Authority
JP
Japan
Prior art keywords
vaccine
cldc
adjuvanted
fish
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011502032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515490A (ja
JP5759890B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/038307 external-priority patent/WO2009120811A1/en
Publication of JP2011515490A publication Critical patent/JP2011515490A/ja
Publication of JP2011515490A5 publication Critical patent/JP2011515490A5/ja
Application granted granted Critical
Publication of JP5759890B2 publication Critical patent/JP5759890B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011502032A 2008-03-25 2009-03-25 カチオン性脂質−dna複合体(cldc)の投与による免疫応答の増強 Expired - Fee Related JP5759890B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3938108P 2008-03-25 2008-03-25
US61/039,381 2008-03-25
PCT/US2009/038307 WO2009120811A1 (en) 2008-03-25 2009-03-25 Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)

Publications (3)

Publication Number Publication Date
JP2011515490A JP2011515490A (ja) 2011-05-19
JP2011515490A5 true JP2011515490A5 (enExample) 2012-05-17
JP5759890B2 JP5759890B2 (ja) 2015-08-05

Family

ID=40791017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502032A Expired - Fee Related JP5759890B2 (ja) 2008-03-25 2009-03-25 カチオン性脂質−dna複合体(cldc)の投与による免疫応答の増強

Country Status (6)

Country Link
US (1) US8945590B2 (enExample)
EP (1) EP2257306B1 (enExample)
JP (1) JP5759890B2 (enExample)
BR (1) BRPI0910036B8 (enExample)
CA (1) CA2719614C (enExample)
WO (1) WO2009120811A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257306B1 (en) 2008-03-25 2014-05-07 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
PL2429581T3 (pl) * 2009-05-14 2016-01-29 Bayer Ip Gmbh Wzmocniona odpowiedź immunologiczna u gatunków ptaków
WO2011106607A2 (en) * 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
LT2654785T (lt) * 2010-12-22 2019-07-10 Bayer Intellectual Property Gmbh Sustiprintas galvijų imuninis atsakas
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015128461A1 (en) 2014-02-28 2015-09-03 Bayer Animal Health Gmbh Immunostimulatory plasmids
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
MX2018001251A (es) 2015-07-31 2018-03-26 Bayer Animal Health Gmbh Respuesta inmunitaria potenciada de las especies porcinas.
WO2017021242A1 (en) * 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in aquatic species
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10918709B2 (en) * 2016-10-31 2021-02-16 Eyegene Inc. Immune modulator and vaccine composition containing the same
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877612A (en) * 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US6121247A (en) 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
WO1999002132A2 (en) * 1997-07-08 1999-01-21 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
EP1872786A1 (en) 1997-09-05 2008-01-02 The Regents of the University of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20090208781A1 (en) * 2008-02-19 2009-08-20 Skinner George A Method for operating a fuel cell system
EP2249843A4 (en) 2008-02-24 2013-05-08 Us Gov Health & Human Serv USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF INFECTIONS BY DISEASES
EP2257306B1 (en) 2008-03-25 2014-05-07 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
US20100137235A1 (en) 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
PL2429581T3 (pl) 2009-05-14 2016-01-29 Bayer Ip Gmbh Wzmocniona odpowiedź immunologiczna u gatunków ptaków

Similar Documents

Publication Publication Date Title
JP2011515490A5 (enExample)
EP2257306B1 (en) Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
EP2720717B1 (en) Vaccine adjuvant composition comprising inulin particles
RU2020117033A (ru) Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение
EP2214705B1 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
JP2009539965A5 (enExample)
Patel et al. Novel drugs targeting Toll-like receptors for antiviral therapy
Riese et al. Vaccine adjuvants: key tools for innovative vaccine design
JP2009511084A5 (enExample)
CN111315407A (zh) 一种广谱抗流感疫苗免疫原及其应用
JP2016506416A5 (enExample)
JP2004527264A5 (enExample)
RU2008119501A (ru) Функциональные вирусоподоюные частицы гриппа (vlps)
JP2010537961A5 (enExample)
Lee et al. Progress and hurdles in the development of influenza virus-like particle vaccines for veterinary use
JP2010520284A5 (enExample)
JP2013522231A5 (enExample)
JP7618632B2 (ja) 経鼻b型肝炎ワクチン組成物およびその製造方法
KR102654379B1 (ko) 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물
RU2018103757A (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
JP2016520077A5 (enExample)
JP2019510064A5 (enExample)
ES2615120T3 (es) Adyuvantes peptídicos
EA200870361A1 (ru) Интраназальное или ингаляционное введение виросом
Kaplina et al. Double-stranded RNAs are promising adjuvants for enhancing immunogenicity of vaccines